利妥昔单抗联合聚乙二醇干扰素-α/利巴韦林与聚乙二醇干扰素-α/利巴韦林在丙型肝炎相关混合性冷球蛋白血症中的比较。
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
机构信息
Department of Internal Medicine, Assistance Publique-Hopitaux de Paris, Groupe Hospitalier Pitié-Salpétrière, Paris, France.
出版信息
Blood. 2010 Jul 22;116(3):326-34; quiz 504-5. doi: 10.1182/blood-2009-10-248518. Epub 2010 May 3.
Treatment of hepatitis C (HCV)-mixed cryoglobulinemia (MC) may target either the viral trigger (HCV) or the downstream B-cell clonal expansion. Prospective cohort study of 38 HCV-MC patients who received a combination of rituximab (375 mg/m(2)) once a week for 1 month followed by Peg-interferon-alpha (Peg-IFN-alpha; 2a, 180 microg or 2b, 1.5 microg/kg) weekly plus ribavirin (600-1200 mg) daily for 48 weeks were compared with 55 HCV-MC patients treated by Peg-IFN-alpha/ribavirin with the same modalities. In the whole population of HCV-MC patients (n = 93), a complete clinical response was achieved in 73.1% (68 of 93), cryoglobulin clearance in 52.7% (49 of 93), and a sustained virologic response in 59.1% (55 of 93). Compared with Peg-IFN-alpha/ribavirin, rituximab plus Peg-IFN-alpha/ribavirin-treated patients had a shorter time to clinical remission (5.4 +/- 4 vs 8.4 +/- 4.7 months, P = .004), better renal response rates (80.9% vs 40% of complete response, P = .040), and higher rates of cryoglobulin clearance (68.4% vs 43.6%, P = .001) and clonal VH1-69(+) B-cell suppression (P < .01). Treatment was well tolerated with 11% of discontinuation resulting from antiviral therapy and no worsening of HCV RNA under rituximab. Our findings indicate that rituximab combined with Peg-IFN-alpha/ribavirin is well tolerated and more effective than Peg-IFN-alpha/ribavirin in HCV-MC.
治疗丙型肝炎（HCV）-混合性冷球蛋白血症（MC）的方法可以针对病毒触发因素（HCV）或下游 B 细胞克隆扩增。对 38 例接受利妥昔单抗（375mg/m²）每周 1 次，连续 1 个月，然后每周给予聚乙二醇干扰素-α（Peg-IFN-α；2a，180μg或 2b，1.5μg/kg）联合利巴韦林（600-1200mg）每日治疗的 HCV-MC 患者进行了前瞻性队列研究，与接受相同方法的 Peg-IFN-α/利巴韦林治疗的 55 例 HCV-MC 患者进行了比较。在 HCV-MC 患者的整个人群（n=93）中，73.1%（93 例中的 68 例）获得完全临床缓解，52.7%（93 例中的 49 例）清除冷球蛋白，59.1%（93 例中的 55 例）获得持续病毒学应答。与 Peg-IFN-α/利巴韦林相比，利妥昔单抗联合 Peg-IFN-α/利巴韦林治疗的患者达到临床缓解的时间更短（5.4+/-4 个月与 8.4+/-4.7 个月，P=0.004），肾脏反应率更高（完全缓解的 80.9%与 40%，P=0.040），冷球蛋白清除率更高（68.4%与 43.6%，P=0.001）和 VH1-69（+）B 细胞克隆抑制率更高（P<0.01）。利妥昔单抗治疗的耐受性良好，抗病毒治疗导致 11%的患者停药，利妥昔单抗治疗后 HCV RNA 无恶化。我们的研究结果表明，利妥昔单抗联合 Peg-IFN-α/利巴韦林治疗 HCV-MC 的疗效优于 Peg-IFN-α/利巴韦林，且耐受性良好。
Zotero 插件